I’ve been researching pitavastain, and I thought it deserved it’s own topic as it has many pleiotropic effects that stand out vs. other statins. Here’s a comparison vs. Atorvastatin (Lipitor).
Key Areas of Divergence
Endothelial Repair and Vessel Regeneration
Pitavastatin: Demonstrates a uniquely strong ability to elevate plasma Vascular Endothelial Growth Factor (VEGF). This signal mobilizes Endothelial Progenitor Cells (EPCs)—specialized stem cells from the bone marrow—to actively travel to and patch up damaged, raw blood vessel linings. [1, 2, 3]
Atorvastatin: Improves overall vascular function primarily by activating existing nitric oxide pathways. However, at standard doses, head-to-head clinical trials indicate it does not increase circulating EPC stem cell numbers or VEGF expression to the same degree as Pitavastatin. [1, 2, 3]
The Inflammation-HDL Link
Pitavastatin: Uniquely ties its anti-inflammatory properties to Apolipoprotein A-I (ApoA-I), the core protein of “good” HDL cholesterol. Studies reveal a significant correlation where Pitavastatin drives down high-sensitivity C-reactive protein (hsCRP) (the primary marker of vessel irritation) specifically as it drives up protective ApoA-I levels. [1, 2]
Atorvastatin: Lowers systemic inflammation (hsCRP) very effectively through standard antioxidant pathways. However, it generally keeps ApoA-I and HDL levels flat or slightly lowered over time, lacking that specific dual protein-inflammation interaction. [1, 2, 3]
Pitavastatin: Displays aggressive baseline suppression of coronary artery smooth muscle cell multiplication. By stopping these muscle cells from multiplying out of control, it reduces the risk of the Carotid Intima-Media Thickness (CIMT) worsening. [1, 2]
Atorvastatin: Also halts arterial wall overgrowth and thick plaque accumulation. However, its control over tissue proliferation is traditionally more dose-dependent, requiring higher clinical doses to match the direct cellular suppression seen with baseline Pitavastatin. [1, 2, 3, 4]
Great idea. When I get some time, I can post a few studies, as pitavastatin indeed has a ton of pleiotropic effects, and is an interesting option to other statins.
Just wanted to share that after many failed attempts with statins in the past (probably over the course of 15–30 years ago), including many different brands and doses as low as 1/4 of a pill 3x per week), at @A_User’s encouragement, I pulled out my long-expired Livalo. So far, I’m noticing very little, if anything.
I may possibly feel ever so slightly more fatigued. Even if that’s real, it doesn’t matter because I still feel well enough to keep taking it for the benefits. I’m soooo happy! (I’m taking 1/2 a pill 3x to week, but I’ll gradually add more to see if I can take one daily… I’m assuming I can!).
If I had to guess what’s different this time, it’s that my health is so much better now that even if I do feel a slight dip, it’s barely noticeable. In the past, I was so plagued by fatigue that anything making it worse was intolerable.
So, once again, thank you all for improving my health!
I switched from 2.5mg Rosuvastatin to 4mg Pitavastatin to match the ApoB reduction (for me personally) and have less aches/pain in the gym than I previously did. I never really believed in the muscle pain side effect of statins so this surprised me. My A1C has also dropped by 0.2%. I’m definitely going to be continuing alongside the 10mg Ezetimibe I was already on. My ApoB was recently 44.
I’ve been looking into the research on pitavastatin, and it’s pretty clear at this point that it significantly increases the risk of new-onset diabetes. There’s no doubt that new-onset diabetes is a class effect of statins. We need to be realistic about what that actually means: irreversible damage to your pancreatic beta cells. As we all know, diabetes isn’t curable. So, it really comes down to weighing the risk-benefit ratio. For biohackers with low baseline cardiovascular risk, is it actually worth taking pitavastatin just to lower that risk a bit more? It’s definitely something worth rethinking.
The comparative risks for NODM with various statins (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) were estimated by both statin exposure versus matched nonexposed and within-class comparisons.the risk for NODM was not significantly different among statins in within-class comparisons. In conclusion, an increased risk for NODM was observed among statin users in a practical healthcare setting in Korea.
Among the five statins, pitavastatin showed the strongest effect on the development of new-onset diabetes.
HMGCR inhibition increased the risk of T2D in SAS, EAS, and EUR cohorts
RCTs, Mendelian randomization, meta-analyses, and observational studies all yield consistent results.
The studies I mentioned earlier are only part of it; I’ve also looked into non-English RCTs, and pitavastatin is by no means an exception among statins. @adssx
Over all studies it’s a mixed bag. There is a trand towards it increasing the risk of developing diabetes but the risk is lower than with other statins.
Results: Of 517 records screened, 13 studies were included, comprising observational studies, and randomized controlled trials. Most of the studies showed pitavastatin to be associated with a lower or no risk of NODM. Meta-analysis revealed that pitavastatin had a lower risk of NODM compared to atorvastatin (RR = 0.86, 95% CI = 0.79-0.93, p = 0.0002) and rosuvastatin (RR = 0.77, 95% CI = 0.71-0.84, p < 0.00001).
More recently, the REPRIEVE trial reported a higher rate of incident diabetes in participants assigned to receive 4 mg pitavastatin daily compared with placebo (RR 1·35, 95% CI 1·09–1·66)
In particular, rosuvastatin and atorvastatin were associated with NODM in many systematic reviews or meta-analyses; however, pravastatin and pitavastatin were found to be associated with lower or no risk.
After 1:2 PSM, 10,238 new pitavastatin users (15,998 person-years of follow-up) and 18,605 atorvastatin + rosuvastatin users (33,477 person-years of follow-up) were pooled from 10 databases. The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin + rosuvastatin (HR 0.72; 95% CI 0.59–0.87). In sub-analysis, pitavastatin was associated with a lower risk of NODM than atorvastatin or rosuvastatin after 1:1 PSM (HR 0.69; CI 0.54–0.88 and HR 0.74; CI 0.55–0.99, respectively). A consistently low risk of NODM in pitavastatin users was observed when compared with low-to-moderate-intensity atorvastatin + rosuvastatin users (HR 0.78; CI 0.62–0.98).
Administration of highest-dose pitavastatin did not increase the risk of NOD in patients at high risk of developing diabetes during the 3-year follow-up. Moreover, various risk factors for NOD such as metabolic syndrome components, glucose intolerance, dyslipidemia, obesity, or hypertension did not affect the development of NOD during pitavastatin administration. Thus, the highest dose pitavastatin can be safely used in patients with metabolic syndrome who are at high risk of developing diabetes.
Regarding whether the diabetogenic effect of statins is a class effect, unlike other statins, pravastatin and pitavastatin are not generally considered as having deleterious effects on glycemic control24,25. In our study, a dose-dependency of statins in NODM was observed in patients treated with rosuvastatin; however, this tendency was not evident in atorvastatin. This difference in the pattern of dose dependency between atorvastatin and rosuvastatin suggests varying degrees of diabetogenicity for different statins.
Yes, I’ve actually looked through those studies. Given the conflicting data out there, I wanted to see if RCTs, Mendelian randomization, meta-analyses, and observational studies consistently align on an increased risk of diabetes. Unfortunately, pitavastatin really isn’t an exception, and the risk is definitely substantial. Looking strictly at RCT data, it shows zero advantage over other statins when it comes to new-onset diabetes risk, which perfectly aligns with the retrospective studies I mentioned earlier.
Look, it’s clear that while pitavastatin still carries a diabetes risk, its long-term use doesn’t raise blood sugar—and can even lower it—compared to other statins. Frankly, that is the only real advantage pitavastatin actually has over the rest of the class.Taking pitavastatin is essentially like taking a standard statin combined with a glucose-lowering drug, but when it comes to actual new-onset diabetes, it really is no different from the others."
I’ve previously shared studies analyzing FDA adverse event reports, and even there, pitavastatin doesn’t carry the lowest risk. Trust me on this—pitavastatin really isn’t an exception.
It’s not just RCTs, Mendelian randomization, meta-analyses, and observational studies; I’ve also looked into a ton of in vitro data. The conclusions lean exactly the way I expected: pitavastatin directly damages pancreatic beta cells, which is precisely why diabetes remains incurable. For biohackers with low baseline cardiovascular risk, you really have to weigh the risk-benefit ratio here.
Human pancreas islet β cells treated with 100 nM atorvastatin, pravastatin, rosuvastatin, and pitavastatin had reduced cell viability (32.12%, 41.09%, 33.96%, and 29.19%, respectively) compared to controls.
@Cole it seems you may be cherry picking the data you choose to acknowledge. Also, the data you’re picking, is it causation or correlation?
Pitavastatin (such as LIVALO or Zypitamag) is a statin used to treat high cholesterol. Unlike some other statins that can increase blood sugar or the risk of new-onset diabetes, pitavastatin is generally considered metabolically neutral. It often has a minimal or no adverse impact on glucose metabolism or HbA1c levels.
Key Interactions & Benefits for Diabetic PatientsNeutral Glycemic Effect: Many studies indicate that pitavastatin does not significantly alter fasting blood glucose or HbA1c in patients with Type 2 diabetes, making it a preferable choice for those who are pre-diabetic or managing diabetes.
Insulin Sensitivity: Some research suggests that due to its chemical structure, pitavastatin can improve insulin sensitivity and support healthy adipocyte function, potentially causing less deterioration to glycemic control than statins like atorvastatin.
Lipid Profile Improvement: Pitavastatin effectively lowers LDL cholesterol while providing sustained increases in HDL (“good”) cholesterol.Guidelines and ConsiderationsCardiovascular Prevention: Because diabetic patients are at a higher risk of cardiovascular events, moderate-intensity statin therapy is a standard treatment recommendation.
Mixed Evidence: While many trials point to its metabolic neutrality, some retrospective cohort studies have shown varying results, with rare instances of pitavastatin being linked to new-onset diabetes. Individual responses can vary.
Mechanistic studies don’t always translate into outcomes due to various reasons. A good example of that is Astralagus, a commonly sold supplement, that directly lengthens telomere length in-vitro but seemingly doesn’t make humans nor mice immortal. The outcome data in humans points to pitavastatin having a slight risk of increasing diabetes rates. Given that heart disease is a bigger issue than diabetes, the benefit outweights the risk. Of course, if you’re a genetic outlier with a natural super low apoB level then you don’t need ot take any statins. And if you have an LDL-C of <100mg/dL, start with just 1mg pitavastatin per day.
I’m also interested in seeing this conversation develop. I have been been following the research both statins for some time. To this point, rosuvastatin is the best match for me because it fits best with my protocol for aggressive Apo(b) reduction.
The two statins have different effects in the brain’s cholesterol management system as well and I think those differences are worth exploring. Rosuvastatin reduces regarding deep parenchymal neuroinflammation, while pitavastatin’s benefits (less data) appear to be more focused on protecting the structural integrity of the blood-brain barrier itself, thereby protecting it from general systematic threats.
So this is all of big interest to me as my latest A1C was 5.7 up from 5.3 3 months ago with no real changes. I am on atorvastatin 10 down from 20 about 6 months ago. On that + Zetia, my LDL is 67. My insulin is 3. I was planning to change to pitavastatin.
Of note my a1c was 5.9 on atorvastatin 20 2 years ago. Lost weight and metformin and it fell to 5.6 but then back to 5.9 on metformin with no weight change. I am now on Jardiance 12.5 and 3+ glucose in urine in the AM fasting. BS was 101. On acarbose with any carbs other than beans for about 6 months. My time course argues against type 1.5 or LADA but I can’t be sure.
My bias runs like this, the vast majority of diabetes in the US is insulin resistance not lack of insulin. Type 1 diabetes is from insulin antibodies but that tends to onset at a young age.
But just how many 50 year olds are getting diabetes from losing islet function rather than resistance? There was a 2022 Stanford study that showed that insulin secretion went up on high dose atorvastatin. Insulin resistance went up even more. The overall conclusion from this 10 week study was that the resistance portion was dominant not some pancreatic toxicity. I am not saying this toxicity doesn’t happen but just that resistance seems to be the dominant mechanism.
Back to selfish me. Up the Jardiance? Pitavastatin? Follow my insulin levels? Pay for Repatha? Or just mostly ignore and just accept that my body wants a bit higher sugar than ideal?
When I wore a monitor, my sugar was near 100 all the time with exercise being the thing that raised it the most.
Dementia is my primary concern based on family history.
Insulin sensitivity was decreased by 24% and insulin secretion by 12% in individuals on statin treatment (at FPG and 2hPG <5.0 mmol/l) compared with individuals without statin treatment (p < 0.01). Decreases in insulin sensitivity and insulin secretion were dose dependent for simvastatin and atorvastatin.
Conclusions/interpretation: Statin treatment increased the risk of type 2 diabetes by 46%, attributable to decreases in insulin sensitivity and insulin secretion.
Correct, the increased risk of diabetes from statins is primarily driven by the dual effects of insulin resistance and pancreatic beta-cell dysfunction.
So 2:1 insulin resistance vs secretion if you can compare in that way. I guess the issue for me is the reversibility of all this. Secretion, of it truly is a pancreatic toxic effect would seem to be irreversible, but everything else would seem more likely to be reversible.
As we all know, the diagnosis of diabetes isn’t really flipping s switch. It is crossing a line that you can come back from at least in regards to the outcome of blood sugars and end organ damage.
Plenty of people lose weight and then have normal blood sugars for a very long time. The sensitivity can be fixed by changing body composition.
Secretion would seem to be significantly less modifiable.
This study had a mean homa-ir of 2.0 without statins which would seem to be a fairly high risk population.
For someone who is fit and metabolically healthy (probably most people here) the risk of developing diabetes due to a low dose stain is extremely low even over a very long time frame
I can’t take metformin, so I am always looking for ways to lower my glucose levels, as I am always on the borderline of pre-type II diabetes.
I switched from atorvastatin to pitavastatin, and my A1c dropped from 5.7 to 5.4. No other changes to my diet or supplement list occurred during the time I started pitavistaten and the blood test.